RxDoctor Payments Data

Victor Muro, MD

Internal Medicine · Las Vegas, NVNPI 1801969381

Payments from drug & device makers

$928in general payments, 2019–2025

Across 72 payments — averaging $12.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$327
  • AstraZeneca$151
  • Boehringer Ingelheim$134
  • GSK$132
  • Novo Nordisk$40
  • Arbor Pharmaceuticals, Inc.$27
  • plus $117 from 6 others

What the payments were for

  • Food & beverage$928100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$928 in reported general payments places this provider in the 70th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$3,947
Medicare patients
12
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter214$229,916
EliquisApixaban182$186,868
Breo ElliptaFluticasone/Vilanterol89$47,101
XareltoRivaroxaban47$44,832
MounjaroTirzepatide20$24,078
TrulicityDulaglutide22$23,533
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$19,154
MyrbetriqMirabegron19$12,890
Lantus SolostarInsulin Glargine,hum.Rec.Anlog93$12,605
Gabapentin202$5,524
Atorvastatin Calcium418$4,099
Fluticasone-VilanterolFluticasone/Vilanterol11$3,442
Omeprazole113$2,646
Levothyroxine Sodium265$2,456
Amlodipine Besylate307$2,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$132$277,018303 claims
PfizerEliquis$327$186,868182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →